Loading...
•
Dec 31, 2021
Acumen Q4 2021 Earnings Report
Acumen reported financial results for the full year ended December 31, 2021, and provided recent business highlights.
Key Takeaways
Acumen Pharmaceuticals reported its full year 2021 financial results, highlighting progress with ACU193 clinical development and corporate team expansion. The company's cash, cash equivalents, and marketable securities totaled $225.9 million as of December 31, 2021, expected to fund operations through 2025.
Advanced ACU193, a monoclonal antibody targeting toxic amyloid-beta oligomers, into clinical testing.
Continued enrollment in INTERCEPT-AD, a Phase 1 clinical trial of ACU193 for early Alzheimer’s disease patients.
Expanded the Acumen team and appointed Kim Drapkin to the Board of Directors.
Reported $225.9 million in cash, cash equivalents, and marketable securities at year-end, anticipated to provide cash runway through 2025.
Acumen
Acumen
Forward Guidance
Acumen Pharmaceuticals anticipates topline results from the INTERCEPT-AD trial in the first half of 2023 and plans to be ready to initiate a Phase 2/3 trial on the success of INTERCEPT-AD results.
Positive Outlook
- INTERCEPT-AD enrollment continues to progress.
- Patient screening and enrollment is ongoing for INTERCEPT-AD at eight active sites, with six additional sites selected for potential activation.
- Acumen anticipates topline results from this trial in the first half of 2023, subject to the rate of site activation and patient recruitment.
- Clinical trial design for INTERCEPT-AD presented at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference.
- Phase 2/3 clinical trial preparation activities progressing.
Challenges Ahead
- Experienced slower than anticipated enrollment due to the COVID-19 pandemic.
- The company expects to report topline results in the first half of 2023.
- Topline results from INTERCEPT-AD trial depend on the rate of site activation and patient recruitment.
- The initiation of Phase 2/3 trial depends on the success of INTERCEPT-AD results.
- Forward-looking statements are subject to certain factors, risks and uncertainties.